TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Artiva Biotherapeutics
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics reported treating over 100 patients with AlloNK across autoimmune and oncology indications, receiving FDA Fast Track Designation for refractory rheumatoid arthritis treatment. The company expects initial clinical response data in first half of 2026 and has $123 million cash runway into Q2 2027.

Insights
ARTV   positive

Company achieved significant clinical milestones, received FDA Fast Track Designation, treated over 100 patients, and maintains strong cash position through Q2 2027